Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAC with GM-CSF vs PIXY321 in Advanced Breast Cancer
NCT00001338Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 1993
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised trial of PIXY321 in chemotherapy-induced thrombocytopenia (CIT) and chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Duration of thrombocytopenia and Time to recovery of platelets to 50,000/microliters. Started Jun 1993; status: completed.
02
Drugs
PIXY321
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT00001338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001338.